A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction

A new, predominantly single chain preparation of recombinant tissue-type plasminogen activator was evaluated to determine coronary thrombolytic efficacy in 100 patients with acute myocardial infarction. At 3.6 +/- 1.2 hours (mean +/- SD) from symptom onset, patients received either intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours) or placebo on a 3:1 randomized, double-blind basis. Coronary angiography, performed 68 +/- 13 minutes after initiation of the study drug infusion, demonstrated patency of the infarct-related artery in 40 (57%) of 70 patients in the tissue plasminogen activator group compared with 3 (13%) of 23 patients in the placebo group (p less than 0.001). Patients in the placebo group were then eligible to receive intracoronary streptokinase. At 90 minutes the patency was observed in 49 (69%) of 71 tissue plasminogen activator patients compared with 5 (24%) of 21 placebo patients (p less than 0.001). At 120 minutes patency was observed in 59 (79%) of 75 patients of the tissue plasminogen activator group and in 10 (40%) of 25 in the intracoronary streptokinase/placebo group. A nadir value of less than 100 mg/dl fibrinogen occurred in 8 (11%) of 73 patients receiving tissue plasminogen activator versus 8 (40%) of 20 patients treated with intracoronary streptokinase (p = 0.002). Moderate or severe bleeding episodes occurred in 39% of patients treated with tissue plasminogen activator compared with 32% of patients who received placebo/intracoronary streptokinase (p = NS). Thus, this tissue plasminogen activator preparation achieves a high rate of recanalization and, at the doses employed, exhibits increased fibrinogen sparing compared with intracoronary streptokinase.

This article has been cited by other articles:

				D. B. Herrick, W. C. Ziai, C. B. Thompson, K. Lane, N. A. McBee, and D. F. Hanley Systemic Hematologic Status Following Intraventricular Recombinant Tissue-Type Plasminogen Activator for Intraventricular Hemorrhage: The CLEAR IVH Study Group Stroke, December 1, 2011; 42(12): 3631 - 3633. [Abstract] [Full Text] [PDF]

				S. Zaitsev, D. Spitzer, J.-C. Murciano, B.-S. Ding, S. Tliba, M. A. Kowalska, O. A. Marcos-Contreras, A. Kuo, V. Stepanova, J. P. Atkinson, et al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation Blood, June 24, 2010; 115(25): 5241 - 5248. [Abstract] [Full Text] [PDF]

				S. Zaitsev, D. Spitzer, J. C. Murciano, B. S. Ding, S. Tliba, M. A. Kowalska, K. Bdeir, A. Kuo, V. Stepanova, J. P. Atkinson, et al. Targeting of a Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis J. Pharmacol. Exp. Ther., March 1, 2010; 332(3): 1022 - 1031. [Abstract] [Full Text] [PDF]

				B.-S. Ding, N. Hong, J.-C. Murciano, K. Ganguly, C. Gottstein, M. Christofidou-Solomidou, S. M. Albelda, A. B. Fisher, D. B. Cines, and V. R. Muzykantov Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature Blood, February 15, 2008; 111(4): 1999 - 2006. [Abstract] [Full Text] [PDF]

				B.-S. Ding, C. Gottstein, A. Grunow, A. Kuo, K. Ganguly, S. M. Albelda, D. B. Cines, and V. R. Muzykantov Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature Blood, December 15, 2005; 106(13): 4191 - 4198. [Abstract] [Full Text] [PDF]

				E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119(2009): 253S - 277S. [Full Text] [PDF]

				M. D. Hill, P. A. Barber, J. Takahashi, A. M. Demchuk, T. E. Feasby, and A. M. Buchan Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke Can. Med. Assoc. J., May 2, 2000; 162(9): 1281 - 1284. [Abstract] [Full Text] [PDF]

				J. Kellett and J. Clarke Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction Med Decis Making, October 1, 1995; 15(4): 297 - 310. [Abstract] [PDF]

				R. W. Smalling, C. Bode, J. Kalbfleisch, S. Sen, P. Limbourg, F. Forycki, G. Habib, R. Feldman, S. Hohnloser, and A. Seals More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction Circulation, June 1, 1995; 91(11): 2725 - 2732. [Abstract] [Full Text]

				C. D. Naylor and S. B. Jaglal Impact of Intravenous Thrombolysis on Short-term Coronary Revascularization Rates: A Meta-analysis JAMA, August 8, 1990; 264(6): 697 - 702. [Abstract] [PDF]

				D. Collen Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator? Ann Intern Med, April 1, 1990; 112(7): 529 - 538. [Abstract] [PDF]

				S. E. Carlson, M. S. Aldrich, H. S. Greenberg, and E. J. Topol Intracerebral Hemorrhage Complicating Intravenous Tissue Plasminogen Activator Treatment Arch Neurol, October 1, 1988; 45(10): 1070 - 1073. [Abstract] [PDF]